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ABSTRACT 
In this paper we explore the impact of electronic commerce on the industry structure and market power allocation of 
China’s pharmaceutical industry. Firstly, we describe the overall characteristics of the pharmaceutical Industry in 
general. Secondly, we develop a value chain based framework of analysis for China’s pharmaceutical industry. We 
divide the pharmaceutical industry value chain into three tiers: the initial market, the middle market and the end market. 
Based on these works, we analyze the profound impacts of Electronic Commerce on the transformation of China’s 
pharmaceutical Industry, with particular emphasis on the evolution of market structure and the re-allocation of market 
power due to the introduction of E-Commerce procedures. 
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1. INTRODUCTION 
 
In this paper we explore the impact of electronic 
commerce on the industry structure and market power 
allocation of China’s pharmaceutical industry. Firstly, 
we will describe the overall characteristics of the 
pharmaceutical Industry in general. Pharmaceutical 
manufacturers in the market could be divided into two 
types: pioneer firms and genetic (imitator) firms, and 
most of the Chinese pharmaceutical manufacturers 
belong to the second group. As for the pharmaceutical 
products, after the introduction of the Pharmaceutical 
Regulation Rules, the taxonomy of medical products in 
China is becoming similar to that of the US, which 
consists of prescription drugs and over-the counter 
drugs. As a result, the market for medical products 
could generally be divided into prescription market and 
over-the-counter market.  
 
Secondly, we develop a value chain based framework of 
analysis for China’s pharmaceutical industry. We divide 
the pharmaceutical industry value chain into three tiers: 
the initial market, the middle market and the end market. 
We focus on the situation of the industry structures and 
market conditions at present. Then in the last part of the 
paper, we analyze the profound impacts of Electronic 
Commerce on the transformation of China’s 
pharmaceutical Industry, with particular emphasis on the 
evolution of market structure and the re-allocation of 
market power due to the introduction of E-Commerce 
procedures. We conclude that pharmaceutical 
manufacturing industry will achieve a new stable 
structure with smaller firm quantity and stronger firm 
power. In wholesaling industry only a few big firms 
would exist in the national market. The three-class agent 
system may disappear. The relative market power of 
retailers will strengthen in the initial market that may 
result in monopsony. And The B2C in pharmaceutical 
retailing industry would pose a chance to re-allocate the 
market share between hospitals and pharmacies. 
 
2. THE OVERVIEW OF PHARMACEUTICAL 
INDUSTRY 
 
Most of the pharmaceutical markets in the world are 
highly monopolized. In 2000 the top ten pharmaceutical 
manufacturers’ market share was 50% in the world. In 
comparison with the word market, Chinese 
pharmaceutical market is highly competitive with a high 
number of manufacturers and distributors. That’s the 
peculiarity of Chinese pharmaceutical industry, which 
we will explicate later. Firstly we’re looking for some 
characteristics of the pharmaceutical Industry in 
general. 
 
The pharmaceutical manufacturers in the market could 
be divided into two types: pioneer and genetic or 
imitator firms. The pioneer firms are companies who 
undertake research and development to discover new 
drugs and bring them to market. They have the patent 
rights of these new drugs, which ensure them to be the 
monopoly before the patent expiration. But the R&D 
and marketing take long time and millions of dollars. 
That leads to a much higher price of the pioneer firm’s 
product compared with that of the imitators’. Some 
famous pioneer firms in the world include Merck and 
Dupont, ect. Only a few of the Chinese pharmaceutical 
manufacturers belong to this group, such as 
Tongrentang. The genetic or imitator firms are smaller 
and don’t do much R&D themselves. They produce 
some “bioquivalent” products to the original branded 
products after the patent expiration, and their prices are 
usually much lower. Most of the Chinese 
pharmaceutical manufacturers belong to this group. 
 
As for the pharmaceutical products, after the 
introduction of the Pharmaceutical Regulation Rules, 
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the taxonomy of medical products in China is becoming 
similar to that of the US, which consists of prescription 
drugs and over-the counter drugs. The over- the-counter 
(OTC) drugs could be bought in any pharmacy. Such as 
vitamins and parts of the antibiotics. This kind of drug’s 
demand is great but no stable, and it’s profits usually are 
not very high. The total revenue in the US drug market 
in 2002 was 214.7 million dollars, the OTC only took 
57.8 million dollars in it. And the sale of prescription 
drugs is controlled strictly. The buyers have to hold a 
prescription by doctors and can only buy the catalog and 
dose of the drug listed on the prescription. This kind of 
drug has much more danger for normal people, but its 
effect is better to the special patients. In fact the 
prescription drugs take the main market share and have 
stable demand. As a result, the market for medical 
products could generally be divided into prescription 
market and over-the-counter market. One of the most 
important characters of prescription drug is that the end 
consumers have less freedom to choose the products at 
their will. Instead, doctors or apothecaries make their 
choices including the category of drugs and also brands 
within the category. The unique type of principal agent 
relationship causes problems in the market such as price 
insensitivity in the retailing market, asymmetric 
information, agency problem, necessary for regulation 
etc. 
 
3. A MARKET TAXONOMY OF THE CHINESE 
PHARMACEUTICAL INDUSTRY AND 
MARKETS ANALYSIS 
 
3.1 Chinese Pharmaceutical Industry Value Chain 
 
Though the revolutions in Chinese pharmaceutical 
industry push the industry closer and closer to the 
international standards. The value chain in China has 
some special characters. See Figure1. 
Manufacturer
Medicine
Governing
Department
&
Insurance
Company
Wholesaler
Hospital
Normal
Pharmacy
Doctor
Patient
          
Figure 1 Chinese pharmaceutical industry Value chain
For example, there is no company like the PMB in US. 
In China the medicine-governing department and 
insurance companies decide what kind of drugs should 
be included in the insurance list. Another important 
feature is that the hospitals also sell medicines as the 
normal pharmacies in China. So Chinese 
pharmaceutical retailers include both the pharmacies 
and hospitals. The hospitals’ market share is over 80% 
in the drug wholesale market. They are the most 
valuable customers to the wholesalers and 
manufacturers. In fact, in the prescription market the 
hospital nearly take almost the whole market share. But 
in the OTC market, the pharmacy’s market share is 
increasing these years. 
 
3.2 A Market Taxonomy Based on Value Chain — 
Three-Class Markets 
 
For convenience we divide the value chain into 
three-class markets and analyze them independently. 
The buyer in the former class market would turn to be 
the seller in the latter market. In this paper all the 
medicine products are thought to be the same (but the 
prescription and over-the-counter still have some 
difference which will be mentioned later). We define 
three-class markets as the initial market, the middle 
market and the end market, in which the sellers and 
buyers are manufacturers and wholesalers, wholesalers 
and retailers, retailers and consumers. 
 
3.3 The Analysis of the Three Markets 
 
3.3.1 The Initial Market 
 
This market is the first market of pharmaceutical 
products. The manufacturers are the sellers, and the 
buyers are wholesalers. 
 
At present there are more than 6000 pharmaceutical 
manufacturers in China. But most of them produce only 
one or several main products. The average firm size is 
very small. The biggest one’s sale revenue is equal to 
1% of the sale revenue in US. The isolation of different 
regions market is very notable. The firms are competing 
intensely and there’s no real industry leader till now. 
Another feature is the manufacturers simply focus on 
production but don’t pay much attention to the 
distribution channel. So they highly relay on the 
downstream firms who handle the market channel. 
That’s why their market power is weak facing the 
distributors and agents.  
 
We subdivide the manufacturers into four types and 
observe the top ten firms’ market share from 1996-2002 
(See Figure 2). It’s clear that the market concentration 
rate is low. In 2002, the four subdivided markets’ CR10 
are 44%, 32%, 18% and 16%. Considering the fact that 
few of the top ten firms in the four subdivided types are 
inter-industry. The market concentration of the whole 
pharmaceutical manufacture is much lower. 
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Figure 2 The total market shares of the top ten 
pharmaceutical manufacturers 
 
As for the wholesalers, the situation is similar. Now 
there are more than 16000 pharmaceutical wholesalers 
in China. Only 5% of them have got the revenue per 
year over ￥ 20,000,000. In 2002, there are 17 
pharmaceutical wholesalers on the list of China top 500 
wholesalers. The total market share of the 17 firm is 
25.88%, CR10=18.98%. Compared with the situation in 
the US and Germany, the market concentration is very 
low. See Figure3  
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Figure 3 The CR3s of three countries’ pharmaceutical 
wholesale industries 
 
To sum up, in the initial market there are a great number 
of manufacturers and most of them have little market 
power which leads to a low market concentration. The 
barriers to entry are actually lower than in some other 
mature product markets. Most of Chinese firms are 
generic firms whose R&D inputs and levels are 
relatively low. To the wholesalers who are the buyers in 
the initial market, there are low barriers to entry. In such 
a situation both the buyers and sellers do not have great 
bargain power. But in the regional markets some 
wholesalers have relatively high monopoly power due 
to the isolation of the markets from competition. 
 
3.3.2 The Middle Market 
 
The wholesalers are sellers in this market. The retailers 
who are the buyers including two groups: pharmacies 
and hospitals. In theory the two kinds of retailers are the 
same, but actually the hospitals have obvious advantage, 
especially in the prescription drug market. They are the 
most important customers to the wholesalers. This tier 
of market has been very inefficient because of the 
wholesalers’ iniquitous performance.  
 
But the situation is changing in these years due to the 
newly adopted policy of the hospital procurement 
bidding system. Though this bidding system has not 
been fledged and adopted by all the firms in the industry. 
It has shown a very attractive tendency. It plans to take 
all the manufacturers, wholesalers and retailers together 
in one system including E-Commerce system and EDI. 
All the information about the drugs such as price, 
producer, agent or wholesalers will be supported in the 
E-Commerce system. The retailers would be able to 
choose the catalog, brand, and the wholesaler as the 
supplier of one product directly and efficiently. And the 
wholesalers and retailers could search and exchange the 
information through EDI. Now the government is trying 
to develop and propel this pharmaceutical industry 
electronic business system. 
  
3.3.3 The end market 
 
The sellers and buyers in this market are retailers and 
consumers. The total demand of the pharmaceutical 
products is very stable and has low price elasticity. The 
agent problem is very marketable in this market. That 
gives the hospital an unshakable advantage. 
 
The demand of every consumer depends on the 
condition that the consumer is in. If the consumer is in 
healthy condition, his demand elasticity is zero but the 
demand is zero also. If the consumer is in ill condition, 
the demand isn’t zero with a very small elasticity. We 
infer it’s a concave function in a limited area whose slop 
changes from zero to infinity. So the end consumer’s 
demand function could be written as a random variable 
D(ω)，ω∈(ω0，ω1)，ω0=（Healthy），ω1=（Sick）, that’s 
the most simple space and the ω1 could be subdivided 
farther. Set P as price, Q as quantity,  we have 
D(ω0) = 0                 (1) 
D(ω1) = Q(P)   with Q’(P)<0 and |Q’’(P)|<0.  (2) 
 
4 APPLICATION OF E-COMMERCE IN THE 
CHINESE PHARMACEUTICAL INDUSTRY 
 
Now the E-Commerce of pharmaceutical industry is just 
at the beginning in China. The trading amount is a quite 
small proportion of the big market. E-Commerce 
emerges mainly in B2B model. And there hasn’t been an 
efficient regulation to this new model of business. But 
it’s growing up in a remarkable speed. More and more 
companies have recognized the coming revolution from 
the new market factor and are going to join the process 
whether they wish it or not. With the government’s 
effort, there is no doubt that the Internet will be a crucial 
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factor of the revolution of pharmaceutical industry in 
China. 
 
In China some successful B2B models are coming in 
sight. Some of them try to build an information center 
and industry database such as www.cpi.ac.cn, 
www.gm.net.cn. Some of them focus on the 
E-commerce Service Provide (ESP) like www.e135.com, 
yy.18-china.com. The main customs of these businesses 
are pharmaceutical manufacturers, wholesalers or agents, 
pharmacies and hospitals. The most important 
investment comes from the relevant departments in 
government and companies. Though their market share 
is not high, the potentiality of them is very large. Such 
as www.e135.com, the trading amount in the first 8 
months went beyond 15 million Yuan. The amount at 
the end of 2000 had reached hundreds of million Yuan.   
 
 
5 THE PROFOUND IMPACT ON CHINESE 
PHARMACEUTICAL INDUSTRY OF 
E-COMMERCE: THE INDUSTRY AND 
MARKET POWER 
 
The E-Commerce of pharmaceutical industry, especially 
the B2B, is being adopted and going to be the new focus 
of the Chinese E-Commerce with the support of 
government. B2C, which has been popular in US, is also 
a hot point in China. These new business models are the 
most immediate impacts of the Internet. 
 
Relatively to the B2C, B2B is more practical in the 
initial market and middle market and may break down 
the original market structure. The Chinese market is has 
some remote regions that are inaccessible to the Internet. 
The barriers to entry of the regional markets are 
becoming lower, which will lead to emergence of more 
enters. So the regional monopoly will face more 
potential competitors and the small firms will have the 
ability to enter more markets. The result is the changes 
of the industry structure and the market power 
allocation of both upstream and downstream firms. 
  
5.1 Manufacture Industry 
 
In the manufacture industry the beneficiary would go to 
the middle firms. The large firms have paid great cost to 
get the national market share during the past time. But 
with the Internet the other smaller firms could get into 
the national market in a much cheaper way. That’s 
impossible in the no-Internet days. So their prices could 
be much lower than that of the large firms’, which 
makes them to be serious competitors to the large firms. 
Though the large firms could apply the Internet to 
decrease their cost too. The past cost and huge 
traditional market nets will be their disadvantages in the 
Internet time. There will not only be the finance 
problem but also the management problems for 
transformation. And there don’t exit such problems for 
the middle and small firms. They only get a new 
competitive advantage from E-Commerce. That may 
lead to a revolution in the industry. 
 
But what’s the problem with the small firms? Why we 
say the winners should be only the middle ones? That’s 
the special situation in China. Now all the 
pharmaceutical manufacturers are facing the GMP 
acceptance. To reach this level the firms have to pay 
much cost to improve the production conditions, 
otherwise they will have to quit. And in the new hospital 
procurement bidding system, some firms are usually not 
the chosen ones. Based on all the policies of recent 
years, we infer that the government wants to push the 
small firms who do not have competitive advantages out 
of this too-crowded industry. That’s the first step to 
solve the problems in the ex-competitive pharmaceutical 
industry. The new competitive advantage supported by 
Internet can’t fight with the government. Additionally 
the small firms in China are highly relied on the local 
markets. But the Internet will break the local market and 
bring all the middle and large firms into every regional 
market. That will be another hit to the small firms. So 
the winners would only be the middle firms who could 
catch this chance. 
 
To conclude, The application of B2B in pharmaceutical 
industry will lead to a new structure: the small firms 
without competitive advantage will quit the market; 
some middle firms will have great development by this 
chance; the big firms have to undergo some revolution 
to deal with the new competitors to protect their market 
shares. More combinations will emerge for expansion, 
some of them will go beyond the regions. 
 
5.2 Wholesaling Industry  
 
In the retailing industry the Internet breaks down the 
limit of regions that is two-way relatively. That means 
in both the upstream and downstream markets the 
wholesalers faces the region limitation. This two-way 
region limitation may be one important reason for the 
low market concentration rate.  
 
Comparing with the manufacture industry, the focus in 
retailing industry is the distribution channels. The 
Internet will break all the market bounders. That means 
every wholesaler will face incredible numbers of 
downstream retailers, which is impossible in the 
traditional market. Then every firm will have chances to 
win some new customers and lose some old costumers. 
That will lead to a higher competition. But the 
government will play an important role here. Similarly 
to the manufacture industry, new hospital procurement 
bidding system will help the powerful firms get more 
market shares in the future, even result in nature 
monopoly. There will be some problems of this method, 
such as the region limitation in retailing market. But the 
Internet would help overcome it. All the firms who win 
the bidding will come to one national market by the 
Internet and compete with each other.  So from both 
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the policy and the technology perspectives, we suggest 
that the government contracts the market and the 
Internet connects the market. 
 
5.3 Retailing Industry 
 
The situation in retailing industry is a little different 
because the region is not the main factor to limit their 
development. And they also use the B2C model that has 
obvious advantage compared with the brick and mortar 
shops. The e-shop is a real sense 24 hours pharmacy and 
lower the consumers’ supply cost and traffic cost. For 
the retailers the e-shop has no fixed cost and little 
running cost. The most attractive point is that it contains 
a no-inventory way during keeping a proper relationship 
with suppliers. Therefore in the future this B2C model 
must become a new focus in retailing market and 
expends the pharmacy’s market share. 
 
6 CONCLUSIONS: SOME PREDICT TO THE 
FUTURE OF CHINESE PGARMACEUTICAL 
INDUSTRY 
 
At last the pharmaceutical manufacturing industry will 
achieve a new stable structure with smaller number of 
firms and stronger firm power that will lead to a higher 
market concentration. The market won’t be divided into 
many regional markets with more beyond-regions 
companies who will compete together in the national 
market. Comparing with before, the manufacturers’ 
market power will strengthen, but the downstream firms 
change also, the relative market power depends on both 
sides. In the wholesaling industry only several big firms 
would exist in the national market. The three-class agent 
system may disappear. The relative market power of 
retailers will strengthen a lot in the initial market that 
may result in a monopsony situation. The B2C business 
model in the pharmaceutical retailing industry denotes a 
chance to re-allocate the market share between hospitals 
and pharmacies. The final structures may be the 
pharmacies and hospitals handle the over-the-counter 
and prescription drugs respectively.  
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